ALLO insider trading
HealthcareAllogene Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Allogene Therapeutics, Inc.
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Company website: allogene.com
ALLO insider activity at a glance
FilingIQ tracks 313 insider transactions for ALLO in filings since Oct 17, 2018. The most recent transaction is dated Aug 21, 2026.
Across the full history, 13 open-market purchases
and 134 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on ALLO insider trades is 51.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest ALLO Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for ALLO?
- FilingIQ tracks 313 Form 4 insider transactions for ALLO (Allogene Therapeutics, Inc.), covering filings from Oct 17, 2018 onwards. 1 of those are dated within the last 90 days.
- Are ALLO insiders net buyers or net sellers?
- Across the full Form 4 history for ALLO, 13 transactions (4%) were open-market purchases and 134 (43%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does ALLO insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is ALLO in?
- Allogene Therapeutics, Inc. (ALLO) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $457.33M.
Methodology & sources
Every ALLO insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.